Hendrika M. Oosterkamp

1.7k citations

26 papers · 441 indexed · h-index 9

Cancer Research top 10%
- Breast Cancer Treatment Studies 10
- Cancer Genomics and Diagnostics 5
- Cancer, Hypoxia, and Metabolism 2
Oncology
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 3
Genetics
- Glioma Diagnosis and Treatment 5
- Chronic Lymphocytic Leukemia Research 2
Molecular Biology
Radiology, Nuclear Medicine and Imaging
Pulmonary and Respiratory Medicine
- Advanced Breast Cancer Therapies 5

Co-authors: Lodewyk F.A. Wessels Sjoerd Rodenhuis Emiel J. Rutgers Juliane Hannemann Cathy A.J. Bosch Marc J. van de Vijver Arno Velds Kenneth O. Lloyd
Cited by: Cancer Research Oncology Genetics
Journals: Journal of Clinical Oncology (6 papers)Cancer Research (1 paper)Clinical Cancer Research (1 paper)
Partner nations: Netherlands United States Germany

In The Last Decade

Hendrika M. Oosterkamp

25 papers receiving 430 citations

Peers

Countries citing papers authored by Hendrika M. Oosterkamp

Since Specialization

Citations

This map shows the geographic impact of Hendrika M. Oosterkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hendrika M. Oosterkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hendrika M. Oosterkamp more than expected).

Fields of papers citing papers by Hendrika M. Oosterkamp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hendrika M. Oosterkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hendrika M. Oosterkamp. The network helps show where Hendrika M. Oosterkamp may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hendrika M. Oosterkamp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hendrika M. Oosterkamp Line = papers co-authored together Hendrika M. Oosterkamp links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial European Journal of Cancer ·Noor Wortelboer,Seamus Kent,Inge R. Konings,Annemiek van Ommen‐Nijhof,Vincent van der Noort,E. van den Pol,Cristina Guerrero Páez,Marlies L. van Bekkum,F. Van den Berkmortel,Helga Droogendijk,Danny Houtsma,Hendrika M. Oosterkamp,Annemieke van der Padt‐Pruijsten,Ester Siemerink,Jolien Tol,Annette A. van Zweeden,A. Elise van Leeuwen‐Stok,Gabe S. Sonke,Agnes Jager,Hedwig M. Blommestein	2025	1
2	Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality npj Breast Cancer ·Noor A. M. Bakker,Hannah Garner,Ewald van Dyk,Elisa Champanhet,Chris Klaver,Maxime Duijst,Leonie Voorwerk,Iris Nederlof,Rosie Voorthuis,Marte C. Liefaard,Marja Nieuwland,Iris de Rink,Onno B. Bleijerveld,Hendrika M. Oosterkamp,Lodewyk F.A. Wessels,Marleen Kok,Karin E. de Visser	2025	4
3	Ribociclib–Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients with Luminal Breast Cancer (BOOG 2017-01) Clinical Cancer Research ·Anne F. de Groot,Danielle Cohen,Joan B. Heijns,Caroline M.P.W. Mandigers,Agnès J. van de Wouw,Marissa Cloos‐van Balen,Joanna A. Ropela,Hendrika M. Oosterkamp,Marlies L. van Bekkum,Danny Houtsma,Hein Putter,Elma Meershoek‐Klein Kranenbarg,Marjolijn Duijm‐de Carpentier,Kyra L. Dijkstra,A. Elise van Leeuwen‐Stok,Sjoerd H. van der Burg,Gerrit‐Jan Liefers,Sabine C. Linn,Judith R. Kroep	2025	0
4	352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03) Annals of Oncology ·Noor Wortelboer,Stephen B. H. Kent,Inge R. Konings,Annemiek van Ommen‐Nijhof,Vincent van der Noort,E. van den Pol,Cristina Guerrero Páez,M. van Bekkum,H.J. Droogendijk,Frans Erdkamp,Danny Houtsma,Hendrika M. Oosterkamp,Annemieke van der Padt‐Pruijsten,E.J. Siemerink,J. Tol,Annette A. van Zweeden,A. Elise van Leeuwen‐Stok,Gabe S. Sonke,Agnes Jager,Hedwig M. Blommestein	2024	1
5	Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery? Breast Cancer Research and Treatment ·M. Loo,Layla Andour,Anne E. van Heesewijk,Hendrika M. Oosterkamp,Gerrit‐Jan Liefers,Marieke E. Straver	2024	3
6	Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer Breast Cancer Research and Treatment ·Joosje C. Baltussen,Simon P. Mooijaart,Annelie Vulink,Danny Houtsma,Wendy M. van der Deure,Elsbeth M. Westerman,Hendrika M. Oosterkamp,Leontine E.A.M.M. Spierings,Frederiek van den Bos,Nienke A. de Glas,Johanneke E.A. Portielje	2024	3
7	89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study Cancers ·Daan G. J. Linders,Marion M. Deken,Martijn A. van Dam,Martin N.J.M. Wasser,Eleonora M. C. Voormolen,Judith R. Kroep,Guus A.M.S. van Dongen,Daniëlle J. Vugts,Hendrika M. Oosterkamp,Marieke E. Straver,Cornelis J.�H. van de Velde,Danielle Cohen,Petra Dibbets‐Schneider,Floris H. P. van Velden,Lenka M. Pereira Arias‐Bouda,Alexander L. Vahrmeijer,Gerrit‐Jan Liefers,Lioe‐Fee de Geus‐Oei,Denise E. Hilling	2023	5
8	FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer Cell Reports ·Sandra Tavares,Nalan Liv,Milena Pasolli,Mark Opdam,Max A. K. Rätze,Manuel Saornil,Lilian Sluimer,Rutger C.C. Hengeveld,Robert van Es,Erik van Werkhoven,Harmjan R. Vos,Holger Rehmann,Boudewijn Burgering,Hendrika M. Oosterkamp,Susanne M.A. Lens,Judith Klumperman,Sabine C. Linn,Patrick W.B. Derksen	2022	7
9	Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01) Breast Care ·Annelot G.J. van Rossum,Ingrid A.M. Mandjes,Erik van Werkhoven,Harm van Tinteren,A. Elise van Leeuwen‐Stok,Petra M. Nederlof,Johanneke E.A. Portielje,Robbert J. van Alphen,Els Platte,Daan van den Broek,Alwin D. R. Huitema,Marleen Kok,Sabine C. Linn,Hendrika M. Oosterkamp,(unknown)	2021	6
10	Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04) European Journal of Cancer ·Annelot G.J. van Rossum,Marleen Kok,Erik van Werkhoven,Mark Opdam,Ingrid A.M. Mandjes,A. Elise van Leeuwen – Stok,Harm van Tinteren,Alexander L.T. Imholz,Johanneke E.A. Portielje,Monique M.E.M. Bos,Aart van Bochove,Jelle Wesseling,Emiel J. Rutgers,Sabine C. Linn,Hendrika M. Oosterkamp	2018	10
11	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study European Journal of Cancer ·Mette S. van Ramshorst,Erik van Werkhoven,Ingrid A.M. Mandjes,Margaret Schot,Jelle Wesseling,Marie-Jeanne T.F.D. Vrancken Peeters,Jetske M. Meerum Terwogt,Monique E.M.M. Bos,Hendrika M. Oosterkamp,Sjoerd Rodenhuis,Sabine C. Linn,Gabe S. Sonke	2017	18
12	Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial British Journal of Cancer ·Nick Beije,Jaco Kraan,Walter Taal,Bronno van der Holt,Hendrika M. Oosterkamp,Anna Maria Elisabeth Walenkamp,Laurens V. Beerepoot,Monique C.J. Hanse,Myra E. van Linde,Antonius T. Otten,René M. Vernhout,Filip Y.F. de Vos,J.W. Gratama,Stefan Sleijfer,Martin J. van den Bent	2015	15
13	USP9X Downregulation Renders Breast Cancer Cells Resistant to Tamoxifen Cancer Research ·Hendrika M. Oosterkamp,E. Marielle Hijmans,Thijn R. Brummelkamp,Sander Canisius,Lodewyk F.A. Wessels,Wilbert Zwart,René Bernards	2014	37
14	O10.05 * FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS Neuro-Oncology ·Walter Taal,Hendrika M. Oosterkamp,Annemiek Walenkamp,Hendrikus J. Dubbink,Laurens V. Beerepoot,Monique C.J. Hanse,Jan Buter,A.H. Honkoop,Dolf Boerman,Filip De Vos,Winand N.M. Dinjens,Roeline Enting,(unknown),Franchette W.P.J. van den Berkmortel,Slinger Jansen,Dieta Brandsma,Jacoline E. C. Bromberg,Irene van Heuvel,René M. Vernhout,Bronno van der Holt,Martin J. van den Bent	2014	3
15	Efficacy and safety of front-line bevacizumab (BEV), weekly paclitaxel (wPAC), and q3w carboplatin (C) in elderly patients (pts) with ovarian cancer (OC): Subgroup analysis of OCTAVIA. Journal of Clinical Oncology ·Antonio González-Martı́n,Laurence Gladieff,Bengt Tholander,Daniel Stroyakovsky,Martin Gore,Hendrika M. Oosterkamp,Alla Lisyanskaya,Andrés Redondo,É. Teissier,Per Rosenberg,Julian Perez Ronco,Ulrich Freudensprung,Sandro Pignata,(unknown)	2013	3
16	Use of perfusion MR imaging for differentiation between tumor progression and pseudo-progression in recurrent glioblastoma multiforme. Journal of Clinical Oncology ·C. Heidemans-Hazelaar,A. Y. Verbeek,Hendrika M. Oosterkamp,Bas van der Kallen,C. J. Vecht	2010	3
17	An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis British Journal of Dermatology ·Hendrika M. Oosterkamp,H. Neering,Sebastian Nijman,Annette M.G. Dirac,W. J. Mooi,René Bernards,Thijn R. Brummelkamp	2006	35
18	Changes in Gene Expression Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer Journal of Clinical Oncology ·Juliane Hannemann,Hendrika M. Oosterkamp,Cathy A.J. Bosch,Arno Velds,Lodewyk F.A. Wessels,Claudette Loo,Emiel J. Rutgers,Sjoerd Rodenhuis,Marc J. van de Vijver	2005	159
19	Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z) International Journal of Cancer ·Hendrika M. Oosterkamp,Linda Scheiner,Maria C. Stefanova,Kenneth O. Lloyd,Connie L. Finstad	1997	55
20	Phase I study of vintriptol, a tryptophan ester of vinblastine European Journal of Cancer and Clinical Oncology ·Hendrika M. Oosterkamp,L.Th Vlasveld,J. Wanders,Jos H. Beijnen,Olaf van Tellingen,Anne-Charlotte Dubbelman,G. Simonetti,H. R. Franklin,Jan B. Vermorken,W.W. ten Bokkel Huinink	1991	7

About Hendrika M. Oosterkamp

Hendrika M. Oosterkamp is a scholar working on Cancer Research, Genetics and Oncology, having authored 26 papers that have together received 441 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (7 papers), Advanced Breast Cancer Therapies (5 papers), Glioma Diagnosis and Treatment (5 papers), Cancer Genomics and Diagnostics (5 papers), HER2/EGFR in Cancer Research (3 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). The work is most often cited by research in Cancer Research (191 citations), Oncology (200 citations) and Genetics (63 citations). Hendrika M. Oosterkamp has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Lodewyk F.A. Wessels, Sjoerd Rodenhuis, Emiel J. Rutgers, Juliane Hannemann, Cathy A.J. Bosch, Marc J. van de Vijver, Arno Velds, Kenneth O. Lloyd, Connie L. Finstad and Thijn R. Brummelkamp. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact